These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7576964)

  • 21. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.
    Poremba C; Hero B; Goertz HG; Scheel C; Wai D; Schaefer KL; Christiansen H; Berthold F; Juergens H; Boecker W; Dockhorn-Dworniczak B
    Klin Padiatr; 2001; 213(4):186-90. PubMed ID: 11528552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
    Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.
    Vega FM; Colmenero-Repiso A; Gómez-Muñoz MA; Rodríguez-Prieto I; Aguilar-Morante D; Ramírez G; Márquez C; Cabello R; Pardal R
    EBioMedicine; 2019 Nov; 49():82-95. PubMed ID: 31685444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of CD44-standard in 182 primary neuroblastomas].
    Christiansen H; Terpe HJ; Gonzales M; Wenderhold S; Berthold F; Lampert F
    Klin Padiatr; 1995; 207(4):219-21. PubMed ID: 7564156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleolin expression has prognostic value in neuroblastoma patients.
    Cangelosi D; Brignole C; Bensa V; Tamma R; Malaguti F; Carlini B; Giusto E; Calarco E; Perri P; Ribatti D; Fonseca NA; Moreira JN; Eva A; Amoroso L; Conte M; Garaventa A; Sementa AR; Corrias MV; Ponzoni M; Pastorino F
    EBioMedicine; 2022 Nov; 85():104300. PubMed ID: 36209521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
    Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
    Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
    Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
    Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
    George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-myc amplification and cell proliferation rate in human neuroblastoma.
    Pession A; Trerè D; Perri P; Rondelli R; Montanaro L; Mantovani W; Derenzini M; Paolucci G
    J Pathol; 1997 Nov; 183(3):339-44. PubMed ID: 9422991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD44 is an independent prognostic factor in early-stage cervical cancer.
    Speiser P; Wanner C; Tempfer C; Mittelböck M; Hanzal E; Bancher-Todesca D; Gitsch G; Reinthaller A; Kainz C
    Int J Cancer; 1997 Apr; 74(2):185-8. PubMed ID: 9133453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.
    Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Ambros P; Ambros I; Ladanyi M; Eddy J; Bonilla MA; Gerald W
    Eur J Cancer; 1997 Oct; 33(12):2117-20. PubMed ID: 9516865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
    Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
    Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.